ArticleJAMA network open2025
Estimated Burden of Influenza and Direct and Indirect Benefits of Influenza Vaccination.
Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Efficacy versus coverage: population-level impacts of vaccination schemes.Infectious Disease Modelling · 2027Article
- Parental preference for live-attenuated versus inactivated influenza vaccination in children: A questionnaire survey.Human vaccines & immunotherapeutics · 2026Article
- Validation of the behavioural and social drivers of influenza vaccine survey in Australia: Cognitive interviews and psychometric evaluation.Human vaccines & immunotherapeutics · 2026Article
- Coverage and appropriateness of influenza vaccination in adults ≥ 60 y: Provider contribution and adherence to Italian national recommendations.Human vaccines & immunotherapeutics · 2026Article
- mRNA-1010 and the Future of Seasonal Influenza Prevention: Towards Next-Generation Respiratory Vaccination.Vaccines · 2026Article
- Hemagglutination Inhibition and Alternate Serologic Responses Following Influenza A(H3N2) Virus Infection.Influenza and other respiratory viruses · 2026Article
- Hemagglutination inhibition and alternate serologic responses following Influenza A(H3N2) virus infection.medRxiv : the preprint server for health sciences · 2026Article
- An agent-based model of the effects of limited vaccination on novel respiratory infections.Journal of clinical epidemiology · 2026Article
- Human Influenza Virus Infection: A Focus on Key Host Determinants Linked to Clinical Disease Severity.Viruses · 2026Review
- Assessment of hemagglutinin-inhibition activity following influenza vaccination during the 2022-2023, 2023-2024, and 2024-2025 seasons.PloS one · 2026Article
- Comparative analysis of influenza epidemiological characteristics in Quzhou, China from 2016 to 2024.Annals of medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Importance: Vaccination is the safest and most effective way to prevent infectious diseases. It not only reduces disease in the vaccinated portion of a population but also potentially provides indirect benefit to the unvaccinated portion. Indirect benefits to the unvaccinated portion in a population are difficult to estimate since indirect benefits cannot be determined from the general population simply. Objective: To estimate the influenza case burden, both direct and indirect, averted by vaccination using an agent-based model, which models agents as individuals in the simulation population. Design, Setting, and Participants: In this decision analytical modeling study, simulations included varied levels of virus transmissibility, vaccine effectiveness, and vaccine uptake among the 2010 Allegheny County, Pennsylvania, census population. Simulations were run from August 15, 2022, to May 31, 2023. Individuals were vaccinated beginning in September of the simulation year. Exposure: Influenza infection. Main Outcomes and Measures: Differences between number of influenza cases in vaccinated and unvaccinated portions of the population. Results: The population used in this study consisted of 1 218 695 agents (median [IQR] age, 40.6 [3.6-77.6] years; 51% female) and was statistically similar in demographics to the 2010 Allegheny County census population. The mean (SD) burden of influenza averted by vaccination with a vaccine effectiveness of 40% ranged from 32.9% (0.9%) in the high transmission scenario to 41.5% (3.4%) in the low transmission scenario for seasonal influenza. In the model, indirect benefit to the unvaccinated portion of the population was found over a range of modeled transmissibility characteristics of seasonal influenza and varied levels of vaccine effectiveness and vaccination coverage; however, direct benefit to the vaccinated portion was greater in all scenarios. At the highest levels of transmissibility, such as might be found in pandemic influenza, indirect benefit decreased and eventually disappeared. Conclusions and Relevance: In this analytical model study, influenza vaccination provided substantial benefit in reducing infections to both the vaccinated and unvaccinated portions of the population. Even when both vaccine effectiveness and vaccine uptake were low, vaccination showed marked reductions in disease burden for transmission levels characteristic of seasonal influenza. However, when the level of transmission was very high, even a highly effective vaccine did not protect unvaccinated individuals. These findings underscore the importance of vaccination in disease prevention and control and show that indirect benefits are limited in high transmission situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.